GlassScriptPhysician profile
Nour Faraj
NPI 1770274730
$1,699.57
in general payments reported to CMS, 2019-2025
21 companies · $745 in 2025
The $745 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $240 · 2024: $714 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $264.59 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $244.49 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $155.55 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $135.37 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $106.85 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $90.00 | 2023-2025 | Verquvo, Belsomra |
| Ardelyx, INC. | $83.72 | 2024-2025 | Ibsrela |
| Abbvie INC. | $81.91 | 2023-2025 | |
| Axsome Therapeutics, INC. | $78.09 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.77 | 2024 | Jardiance |
| Pfizer INC. | $66.42 | 2024-2025 | |
| Amgen INC. | $56.41 | 2024-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $42.61 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $41.84 | 2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $37.47 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.43 | 2025 | Trintellix |
| Ironwood Pharmaceuticals, INC | $29.17 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $26.80 | 2024 | |
| Glaxosmithkline, LLC. | $24.32 | 2025 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $16.00 | 2025 | Uptravi, Opsumit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.76 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nour Faraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.